Passalacqua G, Albano M, Ruffoni S, Pronzato C, Riccio A M, Di Berardino L, Scordamaglia A, Canonica G W
DIMI--Department of Internal Medicine, University of Genoa, Italy.
Am J Respir Crit Care Med. 1995 Aug;152(2):461-6. doi: 10.1164/ajrccm.152.2.7633693.
Studies over 10 yr have demonstrated local nasal immunotherapy (LNIT) to be an effective treatment for rhinitis due to pollens and mites. The aim of our work was to investigate the effects of LNIT on the local inflammatory phenomena, employing the model of nasal allergenic challenge, since no evidence has been yet provided about LNIT effects on the events due to allergic reactions. We evaluated, in addition, the possible effects of LNIT on some systemic immunologic parameters and its clinical efficacy. The study involved a double-blind, placebo-controlled trial of preseasonal immunotherapy with Parietaria in 20 adults. A significant reduction of symptoms, inflammatory infiltration, and intercellular adhesion molecule-1 (ICAM-1) expression on epithelial cells after nasal challenge was evidence as long-lasting effect. No changes in serum allergen-specific IgE, IgG, and soluble eosinophil cationic protein were detected, whereas an unexpected increase of soluble ICAM-1 was found in the placebo group only. The treatment was well tolerated and a significant clinical improvement under natural allergenic exposure was observed in the active group. The present study provides, for the first time, evidence that LNIT is able to modulate the nasal allergic inflammation.
超过10年的研究已证明，局部鼻免疫疗法（LNIT）是治疗花粉和螨虫引起的鼻炎的有效方法。由于尚未有证据表明LNIT对过敏反应相关事件的影响，我们的研究目的是采用鼻过敏原激发模型来研究LNIT对局部炎症现象的影响。此外，我们评估了LNIT对一些全身免疫参数的可能影响及其临床疗效。该研究涉及对20名成年人进行的一项双盲、安慰剂对照的夏枯草花粉季节性免疫疗法试验。鼻激发后症状、炎症浸润以及上皮细胞间细胞黏附分子-1（ICAM-1）表达的显著降低证明了其长期效果。未检测到血清过敏原特异性IgE、IgG和可溶性嗜酸性粒细胞阳离子蛋白的变化，而仅在安慰剂组中发现可溶性ICAM-1意外增加。该治疗耐受性良好，并且在自然过敏原暴露下，活性组观察到显著的临床改善。本研究首次提供了证据表明LNIT能够调节鼻过敏性炎症。
